In a groundbreaking move, OncoNano Medicine, Inc., based in SOUTHLAKE, Texas, has unveiled a pivotal clinical trial supply agreement with none other than Regeneron, heralding a new era in medical collaboration. The stage is set for Libtayo® (cemiplimab), a formidable PD-1 inhibitor, to join forces with ONM-501, a revolutionary dual-activating STING (STimulator of INterferon Genes) agonist and the leading star in therapeutic development.
Prepare for the spectacle that is the ONM-501 first-in-human trial (NCT06022029). This multicenter Phase 1a/b extravaganza takes us on a thrilling journey of dose escalation and expansion. Picture intratumoral ONM-501 stepping into the spotlight, both as a solo act and in mesmerizing harmony with Libtayo, all for the benefit of patients grappling with advanced solid tumors and lymphomas. OncoNano takes center stage as the trial’s visionary sponsor, while Regeneron assumes the role of the cemiplimab supplier, ensuring that the show goes on.
Kartik Krishnan, M.D., Ph.D., the virtuoso Chief Medical Officer of OncoNano Medicine, shares his excitement: “We believe that our ONM-501 program, with its ingenious blend of cyclic dinucleotide activation and polyvalent STING binding, is poised to redefine the clinical landscape compared to previous experimental STING agonists. This collaboration with industry leader Regeneron fuels our mission to deliver precision-targeted therapies to those battling cancer.” The curtain rises on a new era of hope and innovation in the quest to conquer cancer.
About OncoNano Medicine
OncoNano Medicine isn’t just pioneering a new era in cancer care; we’re orchestrating a symphony of innovation that leverages the intricate dance of molecular cooperativity. Our avant-garde approach hinges on harnessing the pH spectrum as a precise biomarker for both diagnosing and treating cancer with unparalleled precision.
Imagine a world where cancer becomes not just a formidable adversary but a puzzle with a solution. OncoNano’s visionary product lineup spans the entire spectrum of cancer care, from powerful solid tumor therapies to groundbreaking real-time image-guided surgery aids. And we’re not stopping there; our immuno-oncology platform is poised to unlock the full potential of the body’s own immune system, directing it with surgical precision to combat cancer.
Leading the charge is pegsitacianine, a revolutionary fluorescent nanoprobe brought to life through our ON-BOARD platform. Pegsitacianine isn’t just another imaging agent; it’s a game-changer in the world of surgical precision. As it hurtles towards a pivotal clinical trial, pegsitacianine aims to redefine the very definition of tumor detection, particularly in cases of peritoneal carcinomatosis.
And that’s just the beginning. Meet ONM-501, our formidable second act—a next-generation STING (STimulator of INterferon Genes) agonist. It’s gearing up for its grand debut in a first-in-human trial, set to unfold in the first half of 2023. Our journey is further enriched by the generous support of grants from the Cancer Prevention Research Institute of Texas, powering the development of both pegsitacianine and ONM-501.
Join us on this exhilarating odyssey as we rewrite the narrative of cancer care, one groundbreaking innovation at a time.